Home › Head and Neck Squamous Cell Carcinoma › Florida › Tampa
Head and Neck Squamous Cell Carcinoma clinical trials in Tampa, FL
15 studies for Head and Neck Squamous Cell Carcinoma are looking for participants at sites in and around Tampa (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
RecruitingPhase 2/3
- Site #0105, Tampa
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RecruitingPhase 1
- Exelixis Clinical Site #8, Tampa
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
RecruitingPhase 1
- ALX Center 7, Tampa
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
RecruitingPhase 3
- Moffitt Cancer Center, Tampa
A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
RecruitingPhase 1
- Moffit Cancer center, Tampa
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
RecruitingPhase 2
- Moffitt Cancer Center-International Plaza, Tampa
- Moffitt Cancer Center - McKinley Campus, Tampa
- Moffitt Cancer Center, Tampa
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
RecruitingPhase 2
- Moffitt Cancer Center-International Plaza, Tampa
- Moffitt Cancer Center - McKinley Campus, Tampa
- Moffitt Cancer Center, Tampa
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
RecruitingPhase 2
- Moffitt Cancer Center-International Plaza, Tampa
- Moffitt Cancer Center - McKinley Campus, Tampa
- Moffitt Cancer Center, Tampa
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
RecruitingPhase 1/2
- Moffitt Cancer Center, Tampa
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
RecruitingPhase 3
- Moffitt Cancer Center, Tampa
A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC
RecruitingPhase 2
- Moffitt Cancer Center, Tampa
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
RecruitingPhase 3
- Tampa General Hospital, Tampa
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
RecruitingPhase 1/2
- Moffitt Cancer Center, Tampa
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
RecruitingPhase 1
- H. Lee Moffitt Cancer Center and Research Institute, Inc, Tampa
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
RecruitingPhase 1/2
- Moffitt Cancer Center, Tampa
Head and Neck Squamous Cell Carcinoma trials in other cities
- Houston, TX47 studies
- Los Angeles, CA42 studies
- Boston, MA40 studies
- New York City, NY39 studies
- Nashville, TN39 studies
- St. Louis, MO28 studies
- Arlington, VA26 studies
- Chicago, IL26 studies
- Philadelphia, PA26 studies
- Atlanta, GA24 studies
- San Antonio, TX22 studies
- Pittsburgh, PA22 studies
Other studies in Tampa
- Non-Small Cell Lung Cancer51 studies
- Breast Cancer43 studies
- Cancer (all types)39 studies
- Colorectal Cancer34 studies
- Acute Myeloid Leukemia29 studies
- Metastatic Cancer29 studies
- Lung Cancer29 studies
- Pancreatic Cancer26 studies
- Ovarian Cancer21 studies
- Melanoma19 studies
- Myelodysplastic Syndromes19 studies
- Prostate Cancer18 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.